Author

Mathew Amprayil Cherian

OU HealthORCID 0000-0002-0380-2012Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Barbara Mensah Sankofi· 1 shared Benjamin F. MilleriD· 1 shared Christopher Charles CossiD· 1 shared Elizabeth A. WellbergiD· 1 shared Haoning Howard CeniD· 1 shared Jasmine M. Manouchehri· 1 shared Jharna Datta· 1 shared Lynn M. MarchoiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

Barbara Mensah Sankofi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cell BiologyCommunications BiologyPeer-reviewedOct 30, 2026

Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipocyte Progenitor Self-Renewal and Adipogenic Differentiation

Nisha S. Thomas, Barbara Mensah Sankofi, Haoning Howard Cen…·Elizabeth A. Wellberg

This study shows tamoxifen reduces subcutaneous adipocyte progenitor self-renewal and adipogenesis by suppressing Wisp2, linking endocrine therapy to metabolic risks like T2D.

DOI 10.1038/s42003-026-11190-z

mousehuman

𝕏 PostBluesky

Cancer BiologyFrontiers in OncologyPeer-reviewedMar 26, 2025

Potent Estrogen Receptor β Agonists with Inhibitory Activity In Vitro, Fail to Suppress Xenografts of Endocrine-Resistant Cyclin-dependent Kinase 4/6 inhibitor-Resistant Breast Cancer Cells

Lynn M. Marcho, Christopher Charles Coss, Menglin Xu…·Mathew Amprayil Cherian

The paper tests the in vivo efficacy of estrogen receptor β agonists combined with tamoxifen in endocrine-resistant breast cancer models, finding no tumor volume reduction despite in vitro success.

2 citations

mouseproteomics

𝕏 PostBluesky